top of page

NCI-2020-13347

P-RAD A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer


 This research study is designed to study a new treatment for triple-negative breast cancer (TNBC). The trial is looking at the effectiveness of a combination of preoperative chemotherapy, pembrolizumab, and different radiation doses. Pembrolizumab is a drug that helps the immune system fight cancer cells. The goal of the trial is to see if adding pembrolizumab and different radiation doses to chemotherapy is safe and effective for women with TNBC.


Triple-negative: It is a type of breast cancer in which cells do not have estrogen receptors (ER), progesterone receptors (PR), and HER-2 receptors.


For more information about the trial, click the link below:

NCI-2020-13347

Clinical Trial Site: Einstein


To see all available clinical trials click here. 



Recent Posts

See All

NCI-2019-07694

Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer (NAPOLI-2) This is a research study called NAPOLI-2. It is designed to see

NCT05908786

A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT IMMUNOTHERAPY COMBINATIONS IN PATIENTS WITH SURGICALLY RESECTABLE HEPATOCELLULAR CAR

NCT05904886

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatoce

Opmerkingen


bottom of page